Nanobiotix Announces Final Phase 1 Data for NBTXR3 Combination Therapy

Nanobiotix said final data from a Phase 1 study evaluating NBTXR3 with immune checkpoint inhibitors as a second-line-or-later therapy for anti-PD-1-resistant primary cutaneous melanoma were presented at the 2026 ESMO Congress.